Updates in the Treatment of Diffuse Large B-cell Lymphoma
Marin F. Xavier, MD, discusses recent updates in diffuse large B-cell lymphoma based on data from the 2021 ASCO Annual Meeting.
Christopher Flowers, MD, discusses the long-term efficacy with tafasitamab-cxix in combination with lenalidomide in diffuse large B-cell lymphoma.
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
5